Form 4: Champions Oncology Director Acquires Stock Options

David Sidransky, a director at Champions Oncology, acquired 21,880 stock options on November 12, 2024.

Summary

• David Sidransky, a director of Champions Oncology, Inc., has reported the acquisition of 21,880 stock options.
• The options were granted on November 12, 2024, at an exercise price of $4.64 per share.
• These options vest over a twelve-month period, with vesting dates on November 12, 2024, February 12, 2025, May 12, 2025, and August 12, 2025.
• The options expire on November 12, 2034.

Sentiment

Score: 7

Explanation: The document indicates a director's increased stake in the company through stock options, which is generally viewed positively by investors.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who have transactions involving company stock or options.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 12 months is also a typical arrangement to align the director's interests with the company's long-term performance.

Stakeholder Impact

• The acquisition of stock options by a director may positively influence shareholder sentiment.

Key Dates

Keywords

stock options, insider trading, director, Champions Oncology, CSBR, equity